Production of thrombopoietin by human carcinomas and its novel isoforms

Yutaka Sasaki, Takayuki Takahashi, Hiroshi Miyazaki, Atsushi Matsumoto, Takashi Kato, Kishiko Nakamura, Sumiko Iho, Yoshiaki Okuno, Kazuwa Nakao

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Thrombocytosis is occasionally seen in patients with carcinomas and has been assumed to be attributable to interleukin-6 or granulocyte-macrophage colony-stimulating factor produced by carcinoma cells. In this study, we clarified whether thrombopoietin (TPO) is involved in carcinoma-associated thrombocytosis. Expression of TPO mRNA was observed in the majority of 27 carcinoma cell lines as determined by reverse transcriptase-polymerase chain reaction (RT-PCR). There were 6 PCR products differing in size; sequence analysis showed the full-length TPO mRNA (TPO-1), 12- and 116-bp deleted variants (TPO-2 and TPO-3, respectively), and 3 novel isoforms (197- and 128- bp deleted forms and a 60-bp insert form of TPO-3; named TPO-4, TPO-5, and TPO-6, respectively). Of 27 lines, 24 expressed TPO-1 mRNA with various other isoforms. Culture supernatants of COS-1 cells transfected with TPO-5 or TPO-6 cDNA did not promote the proliferation of TPO-responsive cells, whereas Western blot analysis on the cell lysates demonstrated TPO-5 but not TPO-6 protein, suggesting poor extracellular secretion (TPO-5) or poor protein synthesis (TPO-6). TPO protein was detected in 10-fold concentrated culture supernatants of cells of these carcinoma lines, with a median concentration of 0.38 fmol/mL as evaluated by enzyme-linked immunosorbent assay. High blood TPO levels were observed with a median value of 3.46 fmol/mL (range, 0.34 to 8.67 fmol/mL) in patients with advanced carcinomas associated with thrombocytosis. These results indicate that thrombocytosis in patients with carcinomas might be caused, at least in part, by TPO produced by carcinoma cells.

Original languageEnglish
Pages (from-to)1952-1960
Number of pages9
JournalBlood
Volume94
Issue number6
Publication statusPublished - 1999 Sep 15
Externally publishedYes

Fingerprint

Thrombopoietin
Protein Isoforms
Carcinoma
Thrombocytosis
Cells
Messenger RNA

ASJC Scopus subject areas

  • Hematology

Cite this

Sasaki, Y., Takahashi, T., Miyazaki, H., Matsumoto, A., Kato, T., Nakamura, K., ... Nakao, K. (1999). Production of thrombopoietin by human carcinomas and its novel isoforms. Blood, 94(6), 1952-1960.

Production of thrombopoietin by human carcinomas and its novel isoforms. / Sasaki, Yutaka; Takahashi, Takayuki; Miyazaki, Hiroshi; Matsumoto, Atsushi; Kato, Takashi; Nakamura, Kishiko; Iho, Sumiko; Okuno, Yoshiaki; Nakao, Kazuwa.

In: Blood, Vol. 94, No. 6, 15.09.1999, p. 1952-1960.

Research output: Contribution to journalArticle

Sasaki, Y, Takahashi, T, Miyazaki, H, Matsumoto, A, Kato, T, Nakamura, K, Iho, S, Okuno, Y & Nakao, K 1999, 'Production of thrombopoietin by human carcinomas and its novel isoforms', Blood, vol. 94, no. 6, pp. 1952-1960.
Sasaki Y, Takahashi T, Miyazaki H, Matsumoto A, Kato T, Nakamura K et al. Production of thrombopoietin by human carcinomas and its novel isoforms. Blood. 1999 Sep 15;94(6):1952-1960.
Sasaki, Yutaka ; Takahashi, Takayuki ; Miyazaki, Hiroshi ; Matsumoto, Atsushi ; Kato, Takashi ; Nakamura, Kishiko ; Iho, Sumiko ; Okuno, Yoshiaki ; Nakao, Kazuwa. / Production of thrombopoietin by human carcinomas and its novel isoforms. In: Blood. 1999 ; Vol. 94, No. 6. pp. 1952-1960.
@article{b3dc004e9a4340b8835c3120a0aeaf17,
title = "Production of thrombopoietin by human carcinomas and its novel isoforms",
abstract = "Thrombocytosis is occasionally seen in patients with carcinomas and has been assumed to be attributable to interleukin-6 or granulocyte-macrophage colony-stimulating factor produced by carcinoma cells. In this study, we clarified whether thrombopoietin (TPO) is involved in carcinoma-associated thrombocytosis. Expression of TPO mRNA was observed in the majority of 27 carcinoma cell lines as determined by reverse transcriptase-polymerase chain reaction (RT-PCR). There were 6 PCR products differing in size; sequence analysis showed the full-length TPO mRNA (TPO-1), 12- and 116-bp deleted variants (TPO-2 and TPO-3, respectively), and 3 novel isoforms (197- and 128- bp deleted forms and a 60-bp insert form of TPO-3; named TPO-4, TPO-5, and TPO-6, respectively). Of 27 lines, 24 expressed TPO-1 mRNA with various other isoforms. Culture supernatants of COS-1 cells transfected with TPO-5 or TPO-6 cDNA did not promote the proliferation of TPO-responsive cells, whereas Western blot analysis on the cell lysates demonstrated TPO-5 but not TPO-6 protein, suggesting poor extracellular secretion (TPO-5) or poor protein synthesis (TPO-6). TPO protein was detected in 10-fold concentrated culture supernatants of cells of these carcinoma lines, with a median concentration of 0.38 fmol/mL as evaluated by enzyme-linked immunosorbent assay. High blood TPO levels were observed with a median value of 3.46 fmol/mL (range, 0.34 to 8.67 fmol/mL) in patients with advanced carcinomas associated with thrombocytosis. These results indicate that thrombocytosis in patients with carcinomas might be caused, at least in part, by TPO produced by carcinoma cells.",
author = "Yutaka Sasaki and Takayuki Takahashi and Hiroshi Miyazaki and Atsushi Matsumoto and Takashi Kato and Kishiko Nakamura and Sumiko Iho and Yoshiaki Okuno and Kazuwa Nakao",
year = "1999",
month = "9",
day = "15",
language = "English",
volume = "94",
pages = "1952--1960",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Production of thrombopoietin by human carcinomas and its novel isoforms

AU - Sasaki, Yutaka

AU - Takahashi, Takayuki

AU - Miyazaki, Hiroshi

AU - Matsumoto, Atsushi

AU - Kato, Takashi

AU - Nakamura, Kishiko

AU - Iho, Sumiko

AU - Okuno, Yoshiaki

AU - Nakao, Kazuwa

PY - 1999/9/15

Y1 - 1999/9/15

N2 - Thrombocytosis is occasionally seen in patients with carcinomas and has been assumed to be attributable to interleukin-6 or granulocyte-macrophage colony-stimulating factor produced by carcinoma cells. In this study, we clarified whether thrombopoietin (TPO) is involved in carcinoma-associated thrombocytosis. Expression of TPO mRNA was observed in the majority of 27 carcinoma cell lines as determined by reverse transcriptase-polymerase chain reaction (RT-PCR). There were 6 PCR products differing in size; sequence analysis showed the full-length TPO mRNA (TPO-1), 12- and 116-bp deleted variants (TPO-2 and TPO-3, respectively), and 3 novel isoforms (197- and 128- bp deleted forms and a 60-bp insert form of TPO-3; named TPO-4, TPO-5, and TPO-6, respectively). Of 27 lines, 24 expressed TPO-1 mRNA with various other isoforms. Culture supernatants of COS-1 cells transfected with TPO-5 or TPO-6 cDNA did not promote the proliferation of TPO-responsive cells, whereas Western blot analysis on the cell lysates demonstrated TPO-5 but not TPO-6 protein, suggesting poor extracellular secretion (TPO-5) or poor protein synthesis (TPO-6). TPO protein was detected in 10-fold concentrated culture supernatants of cells of these carcinoma lines, with a median concentration of 0.38 fmol/mL as evaluated by enzyme-linked immunosorbent assay. High blood TPO levels were observed with a median value of 3.46 fmol/mL (range, 0.34 to 8.67 fmol/mL) in patients with advanced carcinomas associated with thrombocytosis. These results indicate that thrombocytosis in patients with carcinomas might be caused, at least in part, by TPO produced by carcinoma cells.

AB - Thrombocytosis is occasionally seen in patients with carcinomas and has been assumed to be attributable to interleukin-6 or granulocyte-macrophage colony-stimulating factor produced by carcinoma cells. In this study, we clarified whether thrombopoietin (TPO) is involved in carcinoma-associated thrombocytosis. Expression of TPO mRNA was observed in the majority of 27 carcinoma cell lines as determined by reverse transcriptase-polymerase chain reaction (RT-PCR). There were 6 PCR products differing in size; sequence analysis showed the full-length TPO mRNA (TPO-1), 12- and 116-bp deleted variants (TPO-2 and TPO-3, respectively), and 3 novel isoforms (197- and 128- bp deleted forms and a 60-bp insert form of TPO-3; named TPO-4, TPO-5, and TPO-6, respectively). Of 27 lines, 24 expressed TPO-1 mRNA with various other isoforms. Culture supernatants of COS-1 cells transfected with TPO-5 or TPO-6 cDNA did not promote the proliferation of TPO-responsive cells, whereas Western blot analysis on the cell lysates demonstrated TPO-5 but not TPO-6 protein, suggesting poor extracellular secretion (TPO-5) or poor protein synthesis (TPO-6). TPO protein was detected in 10-fold concentrated culture supernatants of cells of these carcinoma lines, with a median concentration of 0.38 fmol/mL as evaluated by enzyme-linked immunosorbent assay. High blood TPO levels were observed with a median value of 3.46 fmol/mL (range, 0.34 to 8.67 fmol/mL) in patients with advanced carcinomas associated with thrombocytosis. These results indicate that thrombocytosis in patients with carcinomas might be caused, at least in part, by TPO produced by carcinoma cells.

UR - http://www.scopus.com/inward/record.url?scp=0033568423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033568423&partnerID=8YFLogxK

M3 - Article

C2 - 10477724

AN - SCOPUS:0033568423

VL - 94

SP - 1952

EP - 1960

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -